|View printer-friendly version|
The number of
Cell Cure is engaged in the research and development of human cell-based therapies for the treatment of retinal and neural degenerative diseases. It is currently focusing its efforts on developing cells for the treatment of macular degeneration as well as working on other neural degenerative diseases. Cell Cure’s lead product under development is OpRegen®, a proprietary formulation of retinal cells designed to provide a long-term therapy for dry age-related macular degeneration, the leading cause of blindness in the aging population. Plans for the development of OpRegen® include filing an application to commence human clinical trials in 2013.
A shelf registration statement of the
This announcement is neither an offer to sell nor a solicitation of an offer to buy any
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing
Peter Garcia, 510-521-3390 ext. 367
Chief Financial Officer
Judith Segall, 510-521-3390 ext. 301
Cell Cure Neurosciences Ltd.
Charles Irving, PhD, +972-2-572-2001
Chief Executive Officer